Stableford Capital II LLC Invests $1.28 Million in Definium Therapeutics, Inc. $DFTX

Posted by Geri Gentry on Sep 9th, 2026

Stableford Capital II LLC acquired a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX – Free Report) in the second quarter, Holdings Channel reports. The institutional investor acquired 27,141 shares of the company’s stock, valued at approximately $1,277,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its position in Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares during the last quarter. Nykredit A S purchased a new stake in shares of Definium Therapeutics in the 2nd quarter valued at approximately $45,000. BNP Paribas Financial Markets lifted its holdings in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares during the last quarter. Allworth Financial LP purchased a new position in shares of Definium Therapeutics during the 2nd quarter worth approximately $110,000. Finally, Caxton Associates LLP acquired a new stake in Definium Therapeutics in the 3rd quarter valued at approximately $126,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Definium Therapeutics

In related news, CEO Robert Barrow sold 29,208 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This trade represents a 2.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. This trade represents a 1.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 67,119 shares of company stock valued at $2,887,496. Company insiders own 2.40% of the company’s stock.

Definium Therapeutics Price Performance

Definium Therapeutics stock opened at $38.23 on Wednesday. Definium Therapeutics, Inc. has a 12-month low of $8.77 and a 12-month high of $49.70. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock has a market cap of $5.14 billion, a P/E ratio of -11.15 and a beta of 2.23. The company has a fifty day simple moving average of $43.35 and a 200-day simple moving average of $29.88.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities analysts expect that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on DFTX. Robert W. Baird upped their price target on Definium Therapeutics from $57.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Maxim Group set a $55.00 target price on Definium Therapeutics and gave the company a “buy” rating in a report on Friday, August 14th. JonesTrading lifted their target price on Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $63.00.

View Our Latest Stock Report on DFTX

Definium Therapeutics Profile

(Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

Stableford Capital II LLC Invests $1.28 Million in Definium Therapeutics, Inc. $DFTX

Insider Activity at Definium Therapeutics

Definium Therapeutics Price Performance

Wall Street Analyst Weigh In

Definium Therapeutics Profile

Further Reading

You might be interested in: